Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TLSA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Foralumab | Secondary Progressive Multiple Sclerosis | Phase 2 · NCT06292923 | Active not recruiting |
| Foralumab Nasal | Multiple System Atrophy | Phase 2 · NCT06868628 | Recruiting |
| Foralumab TZLS-401 100 µg | Non-Active Secondary Progressive Multiple Sclerosis | Phase 2 · NCT06890923 | Recruiting |
| Foralumab TZLS-401 50 µg | Dementia | Phase 2 · NCT06489548 | Recruiting |
| Milciclib | NSCLC | Phase 2 · NCT05651269 | Unknown |
| Milciclib Maleate | Hepatocellular Carcinoma | Phase 2 · NCT03109886 | Completed |
| Intranasal Foralumab Solution | Primary Progressive Multiple Sclerosis | Phase 1 · NCT05029609 | Withdrawn |
Also used in these trials (approved or third-party drugs, not TLSA's own candidates): Dexamethasone, Lenalidomide, Omeprazole, Vorinostat.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TLSA holds $3.2M in cash and short-term investments and burns about $3.3M/quarter from operations, an estimated runway of 2.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 70 · High
These conditions raise substantial doubt about the Group’s ability to continue as a going concern.20-F, May 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TLSA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Gabriele M Cerrone Director, 10% owner |
Insider | 44,814,587 | 37.19% | 2026-07-21 |
| Chernett Jorey | 5%+ holder (13G) | 6,476,471 | 5.37% | 2025-09-30 |
| Ivor Elrifi Chief Executive Officer · +2.10M options |
Insider | 5,843,684 | 4.85% | 2026-08-15 |
| Mid-american Wealth Advisory Group, Inc. | Institution (13F) | 448,667 | 0.37% | 2026-09-30 |
| Keeren Rameshchandra Shah CHIEF OPERATING & FIN. OFFICER |
Insider | 2,500 | 0.00% | 2026-03-18 |
Share count 120,507,401 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-15 filed 2026-09-29 |
Elrifi Ivor |
Option exercise (M) | 1,050,000 | – | – |
| 2026-08-15 filed 2026-09-29 |
Elrifi Ivor |
Option exercise (M) | 1,050,000 | – | 5,843,684 |
| 2026-07-21 filed 2026-08-07 |
CERRONE GABRIELE M |
Purchase (P) | 42,357 | $0.99 | 44,814,587 |
| 2026-06-12 filed 2026-08-07 |
CERRONE GABRIELE M |
Purchase (P) | 15,000 | $1.11 | 44,772,230 |
| 2026-08-05 filed 2026-08-06 |
Elrifi Ivor |
Purchase (P) | 237,616 | $1.00 | 4,793,684 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TLSA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →